Literature DB >> 27067084

Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke.

Gregory Y H Lip1, Peter Brønnum Nielsen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27067084     DOI： 10.1161/CIRCULATIONAHA.115.016713

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.

Authors:  Gregory Y H Lip; Flemming Skjøth; Peter Brønnum Nielsen; Jette Nordstrøm Kjældgaard; Torben Bjerregaard Larsen
Journal:  JAMA Cardiol       Date:  2017-08-01       Impact factor: 14.676

2.  Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation.

Authors:  Peter Brønnum Nielsen; Torben Bjerregaard Larsen; Flemming Skjøth; Gregory Y H Lip
Journal:  JAMA Intern Med       Date:  2017-04-01       Impact factor: 21.873

3.  Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.

Authors:  Shang-Hung Chang; I-Jun Chou; Yung-Hsin Yeh; Meng-Jiun Chiou; Ming-Shien Wen; Chi-Tai Kuo; Lai-Chu See; Chang-Fu Kuo
Journal:  JAMA       Date:  2017-10-03       Impact factor: 56.272

4.  Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis.

Authors:  Kaisaier Wulamiding; Zixuan Xu; Yili Chen; Jiangui He; Zexuan Wu
Journal:  Front Cardiovasc Med       Date:  2022-07-29

5.  Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.

Authors:  Michał Mazurek; Menno V Huisman; Kenneth J Rothman; Miney Paquette; Christine Teutsch; Hans-Christoph Diener; Sergio J Dubner; Jonathan L Halperin; Chang Sheng Ma; Kristina Zint; Amelie Elsaesser; Shihai Lu; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2017-12-06       Impact factor: 5.249
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.